Nanobiotix Shares Climb 4.25% at Close After Technical Day
Nanobiotix shares ended the session on Thursday, January 22, 2026, with a gain of 4.25%, bringing the price to 18.16 euros from 17.42 euros the previous day. This increase occurs in a calmed market environment for the biotech specialized in nanomedicine, which still shows a spectacular performance of 464% over one year.
Mixed Signals from Technical Indicators
Technical indicators are sending mixed signals for Nanobiotix shares. The RSI stands at 36, gradually moving away from the oversold zone at 30, suggesting a possible stabilization after several correction sessions. However, the price remains slightly below its 50-day moving average set at 18.45 euros, indicating short-term investor caution. The MACD indicator displays an unfavorable setup with a MACD line at -0.21 and a negative histogram of -0.08, revealing a dynamic that requires confirmation to reverse sustainably. Crossing the support threshold at 17.24 euros has allowed the stock to breathe, but overcoming the resistance at 19.90 euros remains a goal to achieve for a structural bullish reversal.
Positive Analyst Consensus Amid Technical Hesitations
The French biotech benefits from a positive analyst consensus that contrasts with the current technical hesitations. Oddo BHF maintains its outperform rating with a target price raised to 28 euros in mid-December, representing an appreciation potential of 54.2% compared to the current price. Similarly, Leerink Partners also confirms its optimism with a target raised to 26 euros at the end of November, indicating a potential rise of 43.2%. These opinions reflect confidence in the clinical advances of the flagship product NBTXR3, developed in partnership with Johnson & Johnson. Expectations are particularly focused on the results of the phase 3 study in head and neck cancers, expected to be published in the second quarter of 2027. The recent participation of the management in the J.P. Morgan Healthcare conference in mid-January has helped maintain institutional interest as the group continues its clinical development in several oncological indications.
